Navigation Links
Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
Date:3/10/2013

EMBARGOED UNTIL 7:45 PM ET, Sunday, March 10, 2013, Cleveland: Researchers from Cleveland Clinic and Sweden-based Sahlgrenska University Hospital have found that a commonly used drug to treat anemia in heart failure patients darbepoetin alfa does not improve patients' health, nor does it reduce their risk of death from heart failure.

Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco on March 10 and published simultaneously online by the New England Journal of Medicine.

Initiated in 2006, the RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial involved 2,278 anemic heart failure patients at 453 sites in 33 countries. Patients were randomly given either darbepoetin alfa or placebo. In the darbepoetin alfa group, 50.7 percent of the patients experienced death from any cause or hospitalization for worsening heart failure. In the placebo group, 49.5 percent of the patients experienced similar clinical outcomes. The trial was funded by Amgen, the maker of darbepoetin alfa (trade name: Aranesp).

"This landmark study provides answers to caregivers who treat patients with heart failure complicated by anemia," said James Young, M.D., cardiologist and Chair of the Cleveland Clinic Endocrinology & Metabolism Institute, and co-investigator of the RED-HF trial. "Our findings do not support the use of darbepoetin alfa to treat anemic heart failure patients."

Anemia, the lack of red blood cells, is a common and serious problem in people who suffer from heart failure. It can lead to worse quality of life, higher rates of hospitalization and death. Treatment options have focused on correcting anemia with the use of intravenous iron or drugs that stimulate red blood cells.

"The benefits of erythropoietin-stimulating agents (ESAs) such as darbepoetin alfa to treat patients with heart failure and anemia have been questioned due to contradictory research findings," said Karl Swedberg, M.D., Ph.D., a senior professor at the Sweden-based Department of Medicine, Sahlgrenska University Hospital and co-investigator of the RED-HF trial. "Our study results show that the use of darbepoetin alfa to stimulate the production of red blood cells is an ineffective treatment for patients with heart failure and anemia."

According to the study, researchers found that darbepoetin alfa treatment led to an early and sustained increase in hemoglobin compared with placebo. However, darbepoetin alfa treatment did not reduce the risk of death from any cause or hospitalization from heart failure. Findings suggest that hemoglobin is a marker of poor prognosis in heart failure, rather than a therapeutic target. There were no new safety findings identified in the study. However, researchers observed an increased risk of thrombosis in the darbepoetin alfa group.

Researchers note that further research is needed to identify treatment options for this patient population.


'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-296-6012
Cleveland Clinic
Source:Eurekalert

Related biology news :

1. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
2. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
3. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
4. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
5. New clinical trial explores novel noninvasive colon cancer screening test
6. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
7. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
8. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
9. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
10. AAO-HNS releases updated Clinical Indicators
11. Sequencing works in clinical setting to help -- finally -- get a diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... ... The AMA is happy to announce that $48,000 in scholarships will be ... are created through funds donated by model aviation organizations and individuals, AMA members, and ... Scholarship Committee, which is made up of model aviation pilots and enthusiasts. The committee ...
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... ... 20, 2017 , ... Energetiq Technology , a world ... Chief Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI North ... connecting the electronics manufacturing supply chain. The mission of the SEMI NAAB is ...
(Date:4/20/2017)... April 20, 2017 For today, Stock-Callers.com ... novel drug development and clinical research aimed at treating diseases ... (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. ... ). You can access our complimentary research reports on these ... ...
Breaking Biology Technology: